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ABSTRACT 
Flow-through transduction methods have been developed to overcome physical limitations imposed by 
Brownian motion on retroviral delivery. This method uses net fluid flow of retroviral supernatants through 
a porous membrane on which the target cells are placed. It is shown that in comparison to static transduc-
tion methods, flow-through transductions have the following advantages: (i) flow-through transductions lead 
to transduction rates that exceed those obtained by static transduction; (ii) flow-through transductions lead 
to high transduction rates even at low viral concentrations, eliminating many of the concerns associated with 
the production of high-titer virus supernatants; (iii) flow-through transductions are insensitive to viral titers, 
eliminating the need to produce consistently retroviral supernatants at given virus concentrations; (iv) flow-
through transductions can be carried out without the use of polycations, such as polybrene; and (v) the vol-
u m e of viral supernatants needed for gene transfer can be sharply reduced. Taken together, these advantages 
of flow-through transductions are likely to lead to their widespread use for gene transfer work, both in re-
search and clinical settings. 
OVERVIEW SUMMARY 
Flow-through transduction provides a means by which high 
rates of gene transfer can occur without using high titers of 
virus vector. Reproducibly high numbers of transduced 
cells can be obtained with a wide range of virus titers, thus 
relaxing the requirement of set (high) titers within a trans-
duction protocol. Incorporating flow-through transductions 
within clinical applications of gene therapy may also obvi-
ate the need for large volumes of high-titer virus produced 
by vector producer cell line cultures. 
INTRODUCTION 
RETROVIRUSES ARE THE CURRENT VEHICLE OF CHOICE for Sta-
ble gene delivery and expression in target cells (Ausubel, 
1993), especially for the purpose of gene therapy (Crystal, 1995; 
Hodgson, 1995; Miller, 1992a; Mulligan, 1993). Retrovims-
mediated gene transfer is typically carried out using static trans-
duction protocols, where a liquid layer containing the retrovims 
is placed on top of a bed of target cells. The physics of this 
transduction system may be described by three processes oc-
curting simultaneously (Fig. 1): (i) Brownian motion of the 
retrovims, (ii) decay of the retrovims, and (iii) adsorption, or 
capture, of the retrovirus by the target cell. A retrovirus is a 
colloidal particle with a density similar to that of tissue culture 
medium, 1.16-1.18 g/ml (Lowy, 1985). Its root mean square 
displacement (/) by Brownian motion over time (r) can be de-
scribed by (Einstein, 1905): 
I (1) 
where D is the diffusion coefficient. The numerical value of the 
diffusion constant for a retrovirus can be estimated from the 
Stokes-Einstein equation {e.g., Cussler, 1984) to be approxi-
mately 6.5 X 10~* cm-̂ /sec using a viral diameter of 100 nm 
(Dubois-Dalqef a/., 1984). 
Retroviral half-lives (/q.s) are generally short (Levin and 
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FIG. 1. Static transduction: Physical processes. This sche-
matic shows h o w a retrovims's distance from the target cell bed 
affects the probability of it being adsorbed. The vims close to 
the bed, at rfj, has a high probability of being adsorbed, while 
the vims further away, at d2, decays over the same time period 
and thus cannot reach a target cell. Each retroviras travels an 
average distance / by Brownian motion over the time period of 
interest. 
Rosenak, 1976; Sanes et al. 1986; Layne et al. 1989; Paul et 
al, 1993; Kotani etal, 1994). W e have measured the half-life 
for a murine amphotropic retrovirus produced by the ipCRlP 
cell line (Danos and Mulligan, 1988) to be about 5-8 hr at 37°C 
(Chuck, 1995). Using the appropriate numerical values for the 
diffusion coefficient and half-life in equation (1), w e estimate 
the distance that an average retroviral particle can travel within 
one half-life (/0.5) to be 480-610 p m . Because tissue culture 
procedures typically use liquid depths of 2-5 m m , the major-
ity of retrovirases in the transduction medium above a level of 
480-610 p,m will not be able to reach the cell bed within one 
half-life. Only those particles closest to the target cells will be 
captured efficiently and within the time span of the retroviral 
half-life. W e have shown that retroviruses within 500 p m of 
the target cell bed were able to deliver the gene, whereas vimses 
further away did not contribute toward cell transduction (Chuck, 
1995). 
The importance of distance between the vims particle and 
target is depicted in Fig. 1, which shows a retrovims particle's 
Brownian motion close to the target cell bed {d]) and far from 
the target cell bed (1̂ 2). The retrovirases close to the target bed 
are able to strike it many times, greatly increasing the chance 
of being captured by a target cell receptor. The retrovimses far 
away from the target may travel the same mean distance (/), 
but decay before being adsorbed by the target cells. Thus, by 
relying on Brownian motion to deliver the retroviras to the tar-
get cells, as in static transductions, the rate of viras delivery is 
in large part determined by the proximity of the available 
virases to the target cell, and the time in which the majority of 
virases are still active (the half-life). 
Under such physical limitations, the number of virions reach-
ing the cell bed can be increased by increasing the retroviral 
titers. However, high retroviral titers have proven difficult to 
obtain from retroviral vector producer cell lines (Belmont et al, 
1988; Bodine et al, 1990; Lynch and Miller, 1991; Crystal, 
1995), and low retroviral titers are generally believed to be a 
major limitation of retrovims-mediated gene transfer. Until re-
cently, these low vims titers were limited by the concentration 
of vims that could be produced by retroviral vector producer 
cell lines. With the advent of new techniques for efficiently con-
centrating a retroviras solution (Paul et al, 1993; Kotani et al, 
1994), the number of infectious retrovirus particles per unit vol-
u m e of solution can be increased up to 10- to 30-fold. However, 
there remains the significant problem of variable viral titers pro-
duced by most producer cell lines (Miller, 1992b; Paul et al, 
1993), making it difficult to reproduce yields from different 
preparations of vims solution. This variability m a y be addressed 
on a case-by-case basis using virus concentration methods, but 
combined with the large volumes of viras vector needed for 
clinical trials (Kotani et al, 1994), and the time consumed by 
adjusting the concentrations, the variability in viras yield makes 
the quality of viras solution very difficult to achieve from a 
vims production standpoint. 
The limitations of Brownian motion can be overcome by di-
recting the motion of the viras toward the target cells. Such a 
directed motion can be achieved by fluid flow, where retrovims 
solution is passed through a porous membrane that supports the 
target cells, leading to significant increases in the number of 
successful gene transfer events. This procedure is termed "flow-
through transduction." Using this m o d e of transduction, the suc-
cess of retroviral delivery is no longer dependent on high viral 
titers, and thus will not necessarily be limited by low retrovi-
ral titers. In the present study, the two methods of viras expo-
sure, static and flow-through (Fig. 2A,B), were compared in 
their ability to deliver the vims to the target cells such that suc-
cessful gene transfer occurted. Using static transduction meth-
ods, the number of successfully transduced cells is expected to 
depend on the vims concentration (Belmont et al, 1988; Lynch 
and Miller, 1991; Hughes et al. 1992; Buchschacher, 1993; 
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FIG. 2. Static transduction versus flow-through transduction. 
In static transduction (A), vims solution overlays a bed of tar-
get cells for the transduction period. In flow-through transduc-
tion (B), virus solution flows through the target cell bed for the 
duration of the transduction period. Flow-through transductions 
were always carried out in parallel with static transductions, us-
ing the same preparation of vims solution and the same target 
cell density. 
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and Miller, 1991), and the polybrene level (Kaplan et al, 1967; 
Cometta and Anderson, 1989). Polycations such as polybrene 
are found to be necessary for static retroviral transduction to 
take place, polybrene, especially at high levels, may be toxic 
to some target cells, and thus has not been approved for clini-
cal use. Thus, it is desirable to reduce the dependence of retro-
viral-mediated gene transfer on polybrene. The effects of these 
factors on gene transfer rates in static and flow-through trans-
duction protocols need to be studied and contrasted. W e pre-
sent such a study herein. 
MATERIALS AND METHODS 
Cell culture 
The target cell line NIH-3T3 was seeded at 3,000 cells/cm^ 
in either six-well plates (Costar, Cambridge, M A ) or tissue cul-
ture membranes 1 day prior to transduction. Collagen-coated 
membranes (Transwell-COL^"^ cell culture inserts from Costar) 
were used. The Transwell-COL^'^ membranes are of the depth 
(filter) membrane type with a pore size rating of 0.4 p m , a di-
ameter of 24.5 m m , and a neutral charge. The estimated poros-
ity of the Transwell-COL^^ membrane is -50-60%. The pro-
ducer cell line used was kindly provided by Dr. James Wilson 
(constmction of a similar vector is described in Wilson et al, 
1988) and was produced by transfecting a p M F G vector con-
taining a lacZ gene into t/CRIP (Danos and Mulligan, 1988). 
The retrovims yielded from the producer cell line belonged to 
the murine leukemia vims ( M u L V ) family. All cell lines were 
grown with 1 0 % calf seram supplement (GIBCO, Grand Island, 
N Y ) in D M E M and were cultured at 37°C and 5 % CO2. 
Retrovirus supernatant 
Replication-defective retrovims producer cells were thawed 
every 6 weeks, grown in 10-ml tissue culture dishes (Falcon, 
Becton Dickinson, Franklin Lakes, NJ), and cultured as de-
scribed above. Medium that was conditioned for 24 hr by a con-
fluent monolayer of producer cells was filtered through 0.4-/xm 
pore-sized filters (low protein binding Sterile Acrodisc''"'̂ , 
Gelman, Ann Arbor, MI). The retroviral vector used did not 
contain a secondary marker gene (such as one providing for 
neomycin resistance), and vims concentration was based on 
vims medium harvested from producer cells (grown as de-
scribed above), which was given a unitiess concentration value 
of 1.0. Variable retroviral concentrations were achieved by 
diluting this viras medium (relative retroviral concentra-
tion value = 1.0) with growth medium, polybrene (Aldrich, 
Milwaukee, W I ) was added to 4 pg/ml (unless otherwise 
stated). Negative controls (mock transductions) were prepared 
by adding polybrene (at the same levels as in the vims super-
natant) to growth medium. These controls were cartied out us-
ing both the static and flow-through transduction procedures. 
Retrovirus concentration 
Retrovims supematant (relative retroviral concentration = 
1.0) was concentrated using the Pellicon Tangential Flow 
System (MilUpore, Bedford, M A ) equipped with an ultrafiltra-
tion membrane of 300-kD molecular weight cutoff (Millipore 
# 300,000 N M W L PTMK000C5). Before each concentration, 
the ultrafiltration chamber was sterilized with 6 liters of 400 
ppm sodium hypochlorite solution, flushed with 6 liters of reg-
ular tap water, and stored in 500 ml of 1 % formalin solution. 
O n the day of concentration, the chamber was flushed with 2 
liters of sterile PBS followed by 1 liter of D M E M . To prepare 
the vims concentrate, 1.5 liters of viras supematant was har-
vested, then centrifuged in 50-ml aliquots in a Beckman table 
top centrifuge for 10 min at 1,500 rpm (—400 X g). The virus 
solution was pumped (Millipore peristaltic pump. Model no. 
XX80-EL000) through the ultrafiltration unit at room temper-
ature with an input gauge pressure of less than 5 psi. Filtered 
vims solution was washed with 2 liters of D M E M and recycled 
(concentrated) to a sterile 600-ml IV bag. The media that had 
passed through the membrane was collected and discarded. 
Viras concentration took place over a period of 1 hr, and serum 
was added to the final product at 1 0 % to maintain the stability 
of the viras (measured to be 5-8 hrs at 37°C in 1 0 % seram) 
and to be consistent with the medium used for dilution. The de-
gree of concentration was calculated from the viras medium 
volume reduction: e.g., 1.5 liters of virus medium concentrated 
to 0.105 liter gave a relative vims concentration of 14.3. The 
concentrated retroviral supematant was also filtered through 
0.4-^im pore-sized filters (Gelman, Ann Arbor, MI). Variable 
retroviral concentrations were achieved by diluting the con-
centrated viras supematant (relative retroviral concentration = 
14.3) with growth medium (10% semm). Because some viras 
activity was lost upon concentration {i.e., recovery rates were 
usually less than 1 0 0 % and typically 5 0 % ) , the viral activity of 
the solution diluted from a concentrated stock may not be the 
same as that from unconcentrated viras solution. For example, 
the activity of a solution diluted to relative retroviral concen-
tration of 1.0 from 14.3 may not be the same as the original 
vims harvest (relative retroviral concentration designated as 
1.0). Thus, the virus solutions used for each concentration value 
were derived from the same stock of solution (here, the rela-
tive retroviral concentration was 14.3). Polybrene (Aldrich) was 
added to the solutions at 4 /u-g/ml. 
Static transductions 
Medium was removed from target cell cultures and replaced 
by 2 ml of virus supematant. (A schematic of the procedure 
shown in Fig. 2A.) The cultures were then incubated for the de-
termined transduction time (8-9 hr, as specified in the legend), 
after which static transduction was stopped by removing retro-
vims solution and adding fresh growth medium. Cultures were 
assayed for expression of transduced gene 3-4 days later. 
Because there was no significant difference between the growth 
of transduced cells and mock-transduced cells (Chuck, 1995), 
the transduction efficiencies were expected to remain the same 
throughout the period of cuhure. 
Flow-through transductions 
Viras medium flowed through the seeded Transwell-COL^"^ 
membranes at — 1 ml/hr for up to 9 hr at 37°C. Gravity was 
used to induce the flow. (Schematic shown in Fig. 2B.) (Flow 
times are specified in legend). All transductions were done in 
parallel with static transductions. Flow-through transductions 
were stopped by removing retrovims solution from the reser-
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voir above the target cell bed and adding fresh growth medium. 
Cultures were left to incubate (without media flow) for 3 ^ days 
until the time of assay. 
Flow cytometry 
The product ofthe transduced gene, /S-galactosidase (/3-Gal), 
reacts with fluorescein di-/3-D-galactopyranoside (FDG) to form 
a product that is detectable using flow cytometry. To determine 
the percentage of cells infected, the cells were prepared in the 
following manner. Each cell culture insert was washed three 
times with 2 ml of Hanks' balanced salt solution (HBSS) and 
the cells removed by 1 ml of trypsin (GIBCO) exposure. Fresh 
growth medium was then used to resuspend and wash the cells. 
Reagents from the FluoReporter lacZ gene detection kit from 
Molecular Probes (Eugene, O R ) were used to prepare and stain 
the cells. The cells were incubated in a 37°C water bath for 5 
min and then loaded with substrate by hypotonic shock as fol-
lows: 50 pl of 2 m M F D G was added to each tube at 37°C and 
left to incubate for 90 sec. The tubes were then immersed into 
ice, and 450 pl of ice-cold phosphate-buffered saline (PBS) 
with human IgG (Sigma) and 1 mg/ml propidium iodide (PI) 
was added. Samples tubes were kept in ice until time of assay. 
A Coulter EPICS flow cytometer was used to measure per-
centage of cells transduced. The following three selection cri-
teria were used. First, single cells were selected from a 90LS-
F A L S 2 D dot plot and used to create a red (PI) fluorescence 
histogram. Second, this PI histogram was used to select live 
cells based on their low PI signal. Next, )3-Gal expression from 
these live cells was indicated by amount of signal on a fluo-
rescein fluorescence histogram (Fig. 3), where the fluorescence 
channel number indicates the degree of fluorescein fluores-
cence. In transduced cell populations, these fluorescein his-
tograms usually consisted of two peaks: one representing cells 
positive for /3-Gal expression, the other representing cells neg-
ative for /3-Gal expression. The location of the lower fluores-
cence peak corresponded to the single peak observed with the 
autofluorescence (no F G D staining) and the mock transduction 
controls. The third and final selection was to measure percent-
age of cells in the positive peak (Fig. 3), calculated by divid-
ing the area in the positive fluorescence (transduction) peak by 
the total histogram area. Transduction efficiency is denoted by 
percentage of cells transduced. All samples were assayed within 
6 hr after staining. Replicate samples were ran in the latter half 
of this period, and early samples were reran at the end. N o dif-
ferences in fluorescein signals were observed as a function of 
time of assay. 
RESULTS 
Important to retrovims vector use, we show that increased 
vims concentration will not always lead to increased transduc-
tion rate. Rather, there is an optimal retroviral concentration for 
gene transfer, after which gains in transduction no longer oc-
cur with increased vims concentration. Second, we show the 
number of cells transduced depends on viral titers and poly-
brene levels. These dependencies are compared using the two 
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FIG. 3. Transduction efficiency as measured by flow cytom-
etry. A. A representative histogram is shown depicting the bi-
modal peaks in fluorescein fluorescence (on a log channel num-
ber scale), representing ;S-Gal expression of a partially 
transduced population of cells. Here, 5 4 % percent of the cell 
population expressed the transduced gene, as indicated by the 
percentage of live cells lying above log fluorescence channel 
number 125. B. A histogram of a mock-transduced cell popu-
lation shows 0 % of the cells were transduced. 
Using static transduction methods, the number of cells trans-
duced was found to depend strongly on the vims concentration 
(Fig. 4). As expected, starting with low vims concentration, the 
number of transduced cells increased with increasing viras con-
centration. However, this increase did not continue as the viras 
concentration reached higher levels. Rather, the number of 
transduced cells reached a maximum and declined thereafter 
with increasing viras concentration. Thus, over the vims con-
centration range examined there was an "optimal" vims con-
centration that resulted in the maximal number of transduced 
cells. 
Transduction efficiency as a function of viras concentration 
was also found to depend strongly on polybrene concentration 
(Fig. 4). The polybrene concentrations used ranged ft-om 0 to 
22 /xg/ml. Except in the absence of polybrene where no trans-
duction occurted, the gene transfer rates showed the same de-
pendence on viral concentration (as evidenced by the similar 
shaped profiles): A n apparent peak in the number of success-
fully transduced cells occurred at 0.5 relative viral concentra-
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FIG. 4. Static transduction: Effect of vims and polybrene con-
centrations. Gene transfer as indicated by percentage of cells 
transduced (% Transduced) was measured as a function of vims 
concentration and polybrene levels. Polybrene concentrations 
ranged from 0 to 22 /ig/ml: (D) 0 pg/ml, (•) 4.4 pg/ml, (O) 
13.2 ^ig/ml, (A) 22 pg/ml. Only the static method of trans-
duction was used here, and the transduction period was 8.5 hr. 
Each data point represents the average of two independent sam-
ples. 
tion units. Maximal values ranged from 3 8 % to 5 5 % transduc-
tion with increased levels of polybrene. Further enhancements 
in gene transfer from increased concentrations of polybrene 
were no longer apparent after 13.2 pg/ml. N o evidence of cell 
toxicity was observed for polybrene levels of 13.2 pg/ml or 
less. Some cell toxicity (as detected by — 2 0 % fewer viable cells 
recovered at time of /3-Gal assay) was observed when 22 pg/ml 
polybrene was used. 
The percentage of cells transduced using both the flow-
through and static methods of transduction was measured as a 
function of vims concentration (Fig. 5A). The vims concentra-
tions used spatmed a thousand-fold range. Using either method, 
an apparent peak occurted in each of the profiles of number of 
transduced cells (Fig. 5A). These apparent peak points repre-
sent the maximum number of transduced cells achieved with 
each delivery method, and can each be associated with "opti-
mal" vims concentrations. Unlike the results shown in Fig. 4, 
it is not clear whether these apparent peaks in Fig. 5 represent 
the begiimings of plateaus or tme peaks. 
There was a 10-fold difference between the optimal viras 
concentrations using the two different modes of transduction 
(Fig. 5): 0.6 relative concentration units for flow-through com-
pared with 6 relative concentration units for the static trans-
ductions. There was also an approximately 1.5-fold increase in 
the maximum number of transduced ceUs: 9 0 % ofthe cells were 
transduced using flow-through and 5 8 % for static. It should be 
noted that different batches of vims were used in the experi-
ments described in Figs. 4 and 5. Although the vims solution 
for each experiment was prepared as described in Materials and 
Methods, the activity of each viral preparation can vary, and 
relative concentration values may not cortespond in absolute 
activities between experiments. The greater than 10-fold dif-
ference between static transduction peak locations in Fig. 4 and 
Fig. 5 was attributed to variation in viras activity between the 
viral preparations used. 
For a given viras concentration and target cell number, the 
number of cells transduced using the flow-through method was 
always higher than using the static method (Fig. 5). The en-
hancement in the number of transduced cells was greatest at the 
lowest virus concentrations used (Fig. 5B). Importantly, the 
flow-through method resulted in a consistently high rate of 
transduction over a wide range (more than two logs) of virus 
concentration. N o differences in cell growth among the differ-
ent viras concentration samples or between the methods of 
transduction were observed at time of assay ( 3 ^ days post-
transduction). 
Not only was the flow-through transduction method rela-
tively insensitive to vims concentration, but unlike the static 
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FIG. 5. Flow-through transduction and static transduction: 
Effect of viras concentration. Transduction efficiency (% 
Transduced) as a function of vims concentration was measured 
using flow-through (•) and static (O) methods of transduction 
(A). The concentration range spanned 10^-fold. The transduc-
tion period was 9 hr. Each data point represents the average of 
two independent samples. B. Gene transfer enhancements by 
flow-through transduction were calculated based on the aver-
age percentage of static transductions for each of the viras con-
centrations shown in Fig. 5A. 
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FIG. 6. A. Flow-through and static transduction: Transduction 
kinetics in the absence of polybrene. Transduction efficiency 
(% Transduced) as a function of viras solution exposure 
time (Transduction Time) for flow-through (•) and 
static (O) transductions. N o polybrene was used in the virus so-
lution. Each data point represents the average of two indepen-
dent samples. B. Polybrene dose response. Transduction effi-
ciency as a function of polybrene concentration was measured 
for flow-through (•) and static (O) transductions. The trans-
duction period was 9 hr. Each data point represents the average 
of two independent samples. 
transfer (Fig. 6). The transduction efficiencies as a function of 
time show that over 3 5 % of 3T3 target cells could be trans-
duced within 4 hr without using polybrene, whereas insignifi-
cant numbers of cells were transduced using the static method 
in the absence of polybrene (Fig. 6A). A relative retroviral con-
centration of 0.75 was used for both experiments (Fig. 6A,B). 
The dependence of the two transduction methods on polybrene 
was examined further by varying polybrene levels from 0.44 to 
22 pgjml (Fig. 6B). The flow-through method was much less 
sensitive to the concentration of polybrene than the static 
method. For polybrene concentrations higher than 2.2 /xg/ml, 
the transduction efficiencies increased at a much slower rate for 
the flow-through method as compared to the static method. 
Thus, not only could gene transfer occur to a significant num-
ber of target cells with no or very low polybrene levels, but 
higher polybrene levels became much less efficacious. As ex-
pected, the polybrene levels did not affect the fluid flow rates 
through the porous membranes (data not shown). 
D I S C U S S I O N 
The recognition that Brownian motion limits the number of 
retrovirases that can reach target cells using static transduction 
methods has led to the development of flow-through transduc-
tion. The flow-through method has been shown to be able to 
enhance significantly the number of transductions over that ob-
tained by static methods. In the present study w e show that: (i) 
the number of transduced cells obtained using static transduc-
tion methods is strongly dependent on viras concentration, and 
that a peak number of transduced cells is obtained at an "opti-
mal" vims concentration; (ii) flow-through transductions are 
much less sensitive to viras concentration and a consistentiy 
high number of transduced cell can be obtained over a wide 
range of viras concentrations; and (iii) polybrene is not needed 
to obtain a high number of transduced cells using the flow-
through method. 
It has been documented that the number of transduced cells 
depends linearly on retrovirus concentration at low titers {e.g.. 
Chuck, 1995). The data presented here show that there is a limit 
to this increase and that a maximum or a plateau is reached at 
elevated virus concentrations. Such a plateau has been observed 
by others (Paul et al, 1993), and suggests there is a limit to 
how much increased viral titer can improve retrovirus-mediated 
gene transfer rates. However, because the retrovirus solutions 
used were only concentrated supematants and not purified, it 
should be noted that effects associated with high virus titer can-
not be distinguished from high concentrations of other nonvi-
ral components of the supematant {e.g., growth inhibitors and 
other factors in conditioned medium that may compete with the 
virus for receptor binding). Thus, the optimal vims concentra-
tion values observed here can be more rigorously described as 
the optimal dilutions of the viras supematant used. 
In general, a vims can be considered a multivalent ligand {e.g., 
Lauffenburger and Linderman, 1993). In such cases, the ligand 
concentration is expected to affect the degree of receptor cross-
linking (Wickham et al, 1990; Lauffenburger and Linderman, 
1993). In other ligand-binding systems, different degrees of cross-
linking have been observed to lead to different cellular responses 
{e.g., MacGlashan et al, 1985; Baird et al, 1988). Further, it has 
been proposed that the number of receptors available for bind-
ing is determined by the relative rates of receptor intemalization 
and subsequent receptor recovery (Zigmond et al, 1982). The 
extent of receptor recovery in polymorphonuclear leukocyte cells 
was found to increase, peak, then decrease with ligand concen-
tration (Zigmond et al, 1982). Although the mechanism(s) by 
which a retroviras binds and internalizes has not been fully de-
fined, optimum relationships found in multivalent ligand bind-
ing systems may apply to retroviral entry, and thus determine the 
probability of successful gene transfer. 
The availability of receptors on the cell determines the 
amount of ligand, or viruses, that can bind. Polybrene is be-
lieved to act to reduce electrostatic repulsion between the neg-
atively charged bilipid layers on the virus and the target cell 
(Coelen et al, 1983; Aubin et al, 1994). The effect of poly-
brene on static transductions was found to be significant (Fig. 
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4, 6B). These results suggest that polybrene acts by increasing 
the receptor availability of target cells to transduction. In using 
flow-through to reduce the distance the viras must travel to the 
target cells, the contact frequency of the viras and target cells 
can be increased {e.g., Berg, 1983). Thus, a greater number of 
cell receptors may be apparent to the virus. In using flow-
through to achieve an enhanced contact frequency, the depen-
dence on polybrene to make receptors available is offset. This 
mode of virus delivery is, in principle, also concentration in-
dependent because virus encounter with the target cell is de-
pendent on fluid mechanics rather than random Brownian mo-
tion. Consistent with this expectation, the change in virus 
delivery method was found to reduce significantly the depen-
dence of gene transfer on virus concentration (Fig. 5). Further, 
the adsorption characteristics of the vims to the porous mem-
brane have been found to determine the likelihood of success-
ful gene transfer (Chuck and Palsson, 1996). More importantiy, 
the flow-through method does not rely on the use of polybrene. 
It has been shown that the vims can adsorb directiy to the (neu-
tral-charged) porous membrane in the absence of polybrene, en-
abling the target cells to encounter the adsorbed virus so that 
vims entry can subsequently take place (Chuck and Palsson, 
1996). 
The characteristics of the flow-through method of transduc-
tion may have significant implications for the use of retrovirus-
mediated gene transfer in gene therapy protocols. Flow-through 
transductions lead to transduction rates not achievable by sta-
tic transduction. The ability to obtain high transduction rates 
even at low viral concentrations eliminates most of the con-
cems associated with the production of high-titer viras solu-
tions. The insensitivity to viral titers eliminates the need to pro-
duce consistently retroviral supematants at given viras 
concentrations. Flow-through transductions can be cartied out 
without the use of polycations such as polybrene. Although no 
long-term effects on cell growth were observed with either the 
polybrene or retroviral concentration ranges used, it should be 
noted that any possible toxic effects associated with these so-
lutions can be minimized using flow-through transductions. 
Last, the volume of viral supematants needed for transduction 
can be sharply reduced. Taken together, these advantages of 
flow-through transductions are Ukely to lead to their widespread 
use for gene transfer work, both in research and clinical set-
tings. 
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